Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations

Rebecca J Austin, Jasmin Straube, Claudia Bruedigam, Gabor Pali, Sebastien Jacquelin, Therese Vu, Joanne Green, Julius Gräsel, Lianne Lansink, Leanne Cooper  1 , Shin-Jye Lee, Nien-Tsu Chen, Chung-Wei Lee, Ashraful Haque, Florian H Heidel, Richard D'Andrea, Geoff R Hill, Ann Mullally, Michael D Milsom, Megan Bywater, Steven W Lane

Leukemia. 2020 Apr;34(4):1075-1089; PMID: 31732720

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Sibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, Frank G Rücker, Susanne Lux, Tamara J Blätte, Sabrina Skambraks, Jan Krönke, Florian H HeidelTina M Schnöder, Andrea Corbacioglu, Verena I Gaidzik, Peter Paschka, Veronica Teleanu, Gudrun Göhring, Felicitas Thol, Michael Heuser, Arnold Ganser, Daniela Weber, Eric Sträng, Hans A Kestler, Hartmut Döhner, Lars Bullinger, Konstanze Döhner

Nat Commun. 2019 May 2;10(1):2031; PMID: 31048683

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function

Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH

Leukemia 2018 May;32(5):1211-1221; PMID: 29467485

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R
Sci Transl Med. 2018 Feb 21;10(429); PMID: 29467301

JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation

Edelmann B, Gupta N, Schnöder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Müller P, Braun-Dullaeus RC, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Müller A, Fischer T

J Clin Invest. 2018 Oct 1;128(10):4359-4371; PMID: 30024857

Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl MC, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH and Isermann B

Nature Commun. 2017 Aug 21;8(1):311; PMID: 28827518

Gain of function in Jak2 V617F-positive T-cells

G NishanthD WolleschakC FahldieckT FischerA MullallyF PernerT M SchnöderS JustF H Heidel, D Schlüter

Leukemia. 2017 Apr;31(4):1000-1003; PMID: 28074070

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnoeder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH

Leukemia. 2016 May;30(5):1220-5; PMID: 26487272

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH

Leukemia. 2016 30: 991-995; PMID: 26242463

Epo-induced erythroid maturation is dependent on Plcg1 signaling

Schnöder T, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck, M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH* and Fischer T*

Cell Death Differ. 2015 Jun;22(6):974-85; PMID: 25394487

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy

Bruedigam C, Otzen Bagger F, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW

Cell Stem Cell. 2014 Dec 4;15(6):775-90; PMID: 25479751

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML

Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Dohner K Vasioukhin V, Fischer T and Armstrong SA

J Exp Med. 2013 Jan 14;210(1):15-22; PMID: 23277453

Genetic and Pharmacologic Inhibition of b-Catenin Targets Imatinib Resistant Leukemia Stem Cells in CML

Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW and Armstrong SA

Cell Stem Cell. 2012 Apr 6;10(4):412-24; PMID: 22482506

© 2020 Heidel Research Group